This article is more than 5 years old. Information may no longer be current.
Imiquimod effective for eyelid basal cell carcinoma in small study
Click Here to Manage Email Alerts
Topical imiquimod cream may offer a safe, effective treatment option for patients with nodular basal cell carcinoma of the eyelid, according to a small study by researchers in Germany.
Raveewan Choontanom, MD, and colleagues at University Eye Hospital, M?nster, evaluated the long-term outcomes for five patients treated with a 6-week course of Aldara (imiquimod cream 5%, Graceway Pharmaceuticals) for basal cell carcinoma.
Four of the five patients showed complete clinical resolution of their tumor after treatment. Additionally, none of these four patients showed signs of local recurrence at 3 years follow-up, according to the study
The fifth patient showed no response to treatment, the authors reported.
Patients typically experienced local side effects from the cream, which caused significant discomfort. However, the discomfort disappeared after completing treatment, they noted.
The study is published in the August issue of Graefe's Archive for Clinical and Experimental Ophthalmology.